Dishman Carbogen Amcis subsidiary clears US FDA inspection without observations

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Carbogen Amcis AG cleared its first US FDA inspection at the Vionnaz, Switzerland site
  • No observations or Form 483 notices were issued during the audit
  • Inspection concluded on September 11, 2026
  • Disclosure made under SEBI LODR Regulations 30 and 51
  • Company confirms all global sites remain approved by major regulators
powered bylight_fuzz_icon
50757284

*this image is generated using AI for illustrative purposes only.

Dishman Carbogen Amcis announced that its wholly owned subsidiary, Carbogen Amcis AG, successfully completed its first US Food and Drug Administration inspection at its manufacturing site in Vionnaz, Switzerland.

The inspection concluded on September 11, 2026, with no observations raised by the regulator. The facility did not receive a Form 483 notice, which is typically issued for significant violations or deficiencies found during such audits.

Regulatory Compliance

The company disclosed the outcome pursuant to Regulations 30 and 51 of the SEBI (LODR) Regulations, 2015. The successful clearance underscores the subsidiary’s adherence to strict quality parameters required for the US market.

Dishman Carbogen Amcis stated that this result reflects the company’s strong focus on quality across its global operations. All manufacturing sites worldwide remain approved by major regulatory agencies.

What the Numbers Show

The absence of a Form 483 is a critical operational indicator. In pharmaceutical manufacturing, receiving no observations during a first-time FDA inspection suggests robust process validation and quality control systems are already in place, reducing the risk of future regulatory holds or export bans for products manufactured at the Vionnaz facility.

Historical Stock Returns for Dishman Carbogen Amcis

1 Day5 Days1 Month6 Months1 Year5 Years
-0.14%-5.50%-11.18%+1.67%-38.45%0.0%

How might the successful FDA inspection of the Vionnaz facility impact Dishman Carbogen Amcis's ability to secure new US-based API contracts in 2027?

Will this regulatory clearance accelerate the commercialization timeline for any specific drug candidates currently under development at the Swiss site?

What is the expected contribution of the Vionnaz facility to the company's overall revenue growth over the next three fiscal years?

like17
dislike

Dishman Carbogen Amcis files FY26 BRSR report detailing ESG metrics

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Export sales contributed 94.94% of total net sales in FY26
  • Total waste generation fell to 1,382.93 MT from 1,978.03 MT
  • Health and safety training coverage rose to 94.21%
  • Water withdrawal increased to 117,466 KL from 85,253 KL
powered bylight_fuzz_icon
50155204

*this image is generated using AI for illustrative purposes only.

Dishman Carbogen Amcis has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The filing provides a comprehensive overview of the company’s environmental, social, and governance performance across its operations.

The report highlights that export sales constituted 94.94% of total net sales during FY26. The company operates as a Contract Development and Manufacturing Organisation (CDMO), with 100% of its turnover derived from the manufacturing of bulk drugs and APIs.

What the Numbers Show

A notable divergence exists in employee welfare coverage between permanent staff and contract workers. While 100% of permanent employees received health insurance, 0% of the 715 non-permanent workers were covered by health insurance, though all workers had accident insurance coverage.

Environmental Metrics

The company reported total energy consumption of 109,381.64 GJ, primarily from non-renewable sources. Water withdrawal increased to 117,466 kilolitres from 85,253 kilolitres in the previous year, driven by a significant rise in third-party water usage. Total waste generated decreased to 1,382.93 metric tonnes from 1,978.03 metric tonnes in FY25.

Metric FY26 FY25
Total Energy Consumption (GJ) 109,381.64 122,585.00
Water Withdrawal (KL) 117,466.00 85,253.00
Total Waste Generated (MT) 1,382.93 1,978.03

Social & Governance Updates

Training coverage expanded significantly. Health and safety training reached 94.21% of permanent employees and workers, up from 65.47% previously. Human rights training coverage rose to 88.87%. The company reported zero complaints regarding sexual harassment, discrimination, or child labour. No penalties or fines were imposed on the company or its directors during the year.

  • Turnover for CSR applicability was ₹194.52 crore.
  • Net worth stood at ₹3,882.23 crore.
  • Zero liquid discharge systems are operational at Bavla and Naroda sites.

Historical Stock Returns for Dishman Carbogen Amcis

1 Day5 Days1 Month6 Months1 Year5 Years
-0.14%-5.50%-11.18%+1.67%-38.45%0.0%

How might the complete lack of health insurance for 715 contract workers impact Dishman Carbogen Amcis's ESG ratings and attractiveness to global pharmaceutical clients with strict supplier codes of conduct?

Given the significant increase in water withdrawal driven by third-party usage, what specific mitigation strategies is the company implementing to manage water stress risks at its manufacturing sites?

With 94.94% of revenue derived from exports, how vulnerable is the company's FY27 outlook to potential regulatory shifts or trade tariffs in key international markets like the US and Europe?

like19
dislike

More News on Dishman Carbogen Amcis

1 Year Returns:-38.45%